CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING ANTIRETROVIRAL THERAPY ADMINISTERED EVERY 2-MONTHS IS COST EFFECTIVE FOR THE TREATMENT OF HIV-1 IN SPAIN

被引：0
|
作者：
Moreno Guillen, S. [1 ]
Rivero, A. [2 ]
Ventayol, P. [3 ]
Falco, V. [4 ]
Torralba, M. [5 ]
Schroeder, M. [6 ]
Neches, V. [7 ]
Vallejo-Aparicio, L. A. [7 ]
Mackenzie, I. [8 ]
Turner, M. [9 ]
Harrison, C. [9 ]
机构：
[1] Hosp Ramon & Cajal, Madrid, Spain
[2] Hosp Reina Sofia, Cordoba, Spain
[3] Hosp Univ Son Espases, Palma De Mallorca, Spain
[4] Hosp Valle De Hebron, Barcelona, Spain
[5] Hosp Univ Guadalajara, Guadalajara, Spain
[6] ViiV Healthcare, Brentford, England
[7] GSK, Tres Cantos, Spain
[8] Hlth Econ & Outcomes Res Ltd, Stratford Upon Avon, War, England
[9] Hlth Econ & Outcomes Res Ltd, Cardiff, Crf, Wales
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE345
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [31] Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy
    Moffatt, Kurtis
    Tekko, Ismaiel A.
    Vora, Lalitkumar
    Volpe-Zanutto, Fabiana
    Hutton, Aaron R. J.
    Mistilis, Jessica
    Jarrahian, Courtney
    Akhavein, Nima
    Weber, Andrew D.
    McCarthy, Helen O.
    Donnelly, Ryan F.
    PHARMACEUTICAL RESEARCH, 2023, 40 (07) : 1673 - 1696
  • [32] Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida
    Fisk-Hoffman, Rebecca J.
    Ranger, Sashaun S.
    Gracy, Abigail
    Gracy, Hannah
    Manavalan, Preeti
    Widmeyer, Maya
    Leeman, Robert F.
    Cook, Robert L.
    Canidate, Shantrel
    AIDS PATIENT CARE AND STDS, 2024, 38 (06) : 275 - 285
  • [33] Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 infection switching to long-acting cabotegravir and rilpivirine
    Rubenstein, E.
    Diemer, M.
    Goldwirt, L.
    Lascoux-Combe, C.
    Lafaurie, M.
    Ponscarme, D.
    Denis, B.
    De Castro, N.
    Rami, A.
    Sellier, P. -O.
    Deville, L.
    Chaix, M. -L.
    Delaugerre, C.
    Molina, J. -M.
    HIV MEDICINE, 2023, 24 : 481 - 482
  • [34] Long-acting injectable antiretroviral therapy for HIV-1 infection in adults
    Halani, Sheliza
    Tan, Darrell
    Andany, Nisha
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (10) : E341 - E342
  • [35] State of the ART (antiretroviral therapy): Long-acting HIV-1 therapeutics
    Ravichandran, Shreya M.
    McFadden, William M.
    Snyder, Alexa A.
    Sarafianos, Stefan G.
    GLOBAL HEALTH & MEDICINE, 2024, 6 (05): : 285 - 294
  • [36] An evaluation of long-acting cabotegravir plus rilpivirine for the treatment of virologically suppressed adults living with HIV
    Qazzaz, Hamdi
    Parganas, Christopher
    Cory, Theodore James
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (13) : 1485 - 1495
  • [37] Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study
    Parker, Ben
    Ward, Tom
    Hayward, Olivia
    Jacob, Ian
    Arthurs, Erin
    Becker, Debbie
    Anderson, Sarah-Jane
    Chounta, Vasiliki
    Van de Velde, Nicolas
    PLOS ONE, 2021, 16 (02):
  • [38] Comparability of 48-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 8 weeks to standard of care in patients with suppressed HIV-1
    Chounta, V.
    Snedecor, S.
    Van de Velde, N.
    HIV MEDICINE, 2020, 21 : 28 - 29
  • [39] Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals
    Cossu, Maria Vittoria
    Cattaneo, Dario
    Moschese, Davide
    Giacomelli, Andrea
    Soloperto, Sara
    D'Avolio, Antonio
    Antinori, Spinello
    Gori, Andrea
    Rizzardini, Giuliano
    Gervasoni, Cristina
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (05) : 1126 - 1132
  • [40] Indirect comparison of 96-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 2 months versus dolutegravir/abaca-vir/lamivudine in suppressed HIV-1 infected participants
    Snedecor, S. J.
    Schroeder, M. D.
    Scherzer, J.
    Van de Velde, N.
    HIV MEDICINE, 2021, 22 : 119 - 119
12345